Recent Advances in the Diagnosis and Management of Malignant Pleural Effusions

JOHN E. HEFFNER, MD, AND JEFFREY S. KLEIN, MD

Malignant pleural effusions (MPEs) are an important complication for patients with intrathoracic and extrathoracic malignancies. Median survival after diagnosis of an MPE is 4 months. Patients can present with an MPE as a complication of far-advanced cancer or as the initial manifestation of an underlying malignancy. Common cancer types causing MPEs include lymphomas, mesotheliomas, and carcinomas of the breast, lung, gastrointestinal tract, and ovaries. However, almost all tumor types have been reported to cause MPEs. New imaging modalities assist the evaluation of patients with a suspected MPE; however, positive cytologic or tissue confirmation of malignant cells is necessary to establish a diagnosis. Even in the presence of known malignancy, up to 50% of pleural effusions are benign, underscoring the importance of a firm diagnosis to guide therapy. Rapidly evolving interventional and histopathologic techniques have improved the diagnostic yield of standard cytology and biopsy. Management of an MPE remains palliative; it is critical that the appropriate management approach is chosen on the basis of available expertise and the patient's clinical status. This review summarizes the pathogenesis, diagnosis, and management of MPE. Studies in the English language were identified by searching the MEDLINE database (1980-2007) using the search terms *pleura*, *pleural*, *malignant*, *pleurodesis*, and *thoracoscopy*.

***Mayo Clin Proc.* 2008;83(2):235-250**

CT = computed tomography; EGFR = epidermal growth factor receptor; FDG = fluorine 18–labeled fluorodeoxyglucose; LDH = lactate dehydrogenase; MPE = malignant pleural effusion; MRI = magnetic resonance imaging; PCR = polymerase chain reaction; PET = positron emission tomography; PF = pleural fluid; SMRP = serum mesothelin-related protein; VATS = video-assisted thoracoscopic surgery

Malignant pleural effusions (MPEs), which comprise a heterogeneous group of conditions, represent an important source of morbidity for patients with underlying cancer. They can occur as the initial presentation of cancer, as a delayed complication in patients with previously diagnosed malignancies, or as the first manifestation of cancer recurrence after therapy. Malignant pleural effusions can result from primary malignancies of the pleurae or from underlying intrathoracic or extrathoracic malignancies that reach the pleural space by hematogenous, lymphatic, or contiguous spread. Although virtually any malignant cell type can cause an MPE, more than 75% of MPEs are caused by neoplasms of the lung, breast, or ovary or by lymphomas.[1-4] Metastatic adenocarcinoma is the most common tumor type.[5] Mesotheliomas develop from malignant transformation of mesothelial cells in the pleural membranes.[6] Regardless of the etiology of an MPE, the median survival from clinical recognition is 4 months; however, prolonged survival is possible in some patients.[7]

This article reviews the current evidence on the pathogenesis, diagnosis, and management of MPEs. Relevant studies in the English language were identified by searching the MEDLINE database (1980-2007) using the search terms *pleura*, *pleural*, *malignant*, *pleurodesis*, and *thoracoscopy* and by hand searching selected reference lists.

PATHOGENESIS

An MPE is defined by the presence of cancer cells in the pleural space. Metastatic MPEs result from direct extension of malignant cells from an adjacent cancer (such as malignancies of the lung, breast, and chest wall), invasion of the pulmonary vasculature with embolization of tumor cells to the visceral pleura, or hematogenous metastases from distant tumors to the parietal pleura. Once established in the pleural space, tumor deposits spread along parietal pleural membranes and obstruct lymphatic stomata, which drain intrapleural fluid. Pleural tumor deposits also stimulate the release of chemokines that increase vascular and pleural membrane permeability, thereby promoting pleural effusions.[8,9] Patients with cancer can develop pleural effusions as an indirect effect of cancer even when cancer cells are absent from the pleural space. These effusions, termed paraneoplastic or paramalignant effusions, can result from mediastinal lymph node tumor infiltration, bronchial obstruction, radiochemotherapy, pulmonary embolism, superior vena cava syndrome,[10] or decreased oncotic pressure.[11]

Between 20% and 30% of patients with non-Hodgkin lymphoma and Hodgkin disease develop pleural effusions.[9] Most effusions in patients with Hodgkin disease are paraneoplastic and result from thoracic duct obstruction. Most patients with effusions due to non-Hodgkin lymphoma have T-cell–type lymphomas and direct pleural infiltration.[9] Nevertheless, non-Hodgkin lymphoma is the most common malignancy-related cause of chylous pleural effusions.[4]

From the Department of Medicine, Providence Portland Medical Center and Oregon Health and Sciences University, Portland (J.E.H.); and Department of Radiology, University of Vermont Medical Center, Burlington (J.S.K.).

Address correspondence to John E. Heffner, MD, Providence Portland Medical Center, 5040 NE Hoyt St, Ste 540, Portland, OR 97213 (e-mail: john_heffner@mac.com).



FIGURE 1. Left, Frontal chest radiograph of a 54-year-old man with a mass on the left kidney and dyspnea showing a moderate-sized right pleural effusion without unique diagnostic features of a malignant effusion. Right, Contrast-enhanced computed tomogram with mediastinal windows showing a right pleural effusion with irregular thickening of the parietal pleura (arrows). Computed tomography–guided pleural biopsy revealed metastatic renal cell carcinoma.

Patients with lymphoma usually do not present with an isolated pleural effusion in the absence of other signs of lymphoma. An exception is primary effusion lymphoma, which is typically a large-cell lymphoma that exclusively or predominantly involves serous cavities without clinically apparent solid tumor mass elsewhere. These body-cavity lymphomas have been reported primarily in patients with AIDS complicated by herpesvirus/human herpesvirus 8 infections. These patients might or might not have coexisting Kaposi sarcoma. Pleural fluid (PF) generation in primary effusion lymphoma appears mediated by vascular endothelial growth factor or vascular permeability factor, which alters permeability of vascular and pleural membranes.[8,9] Patients with chronic intrapleural infections can develop pyothorax-associated lymphoma as a unique expression of a non-Hodgkin lymphoma.[12]

DIAGNOSIS

Patients with MPEs present with nonspecific histories and physical findings and require cytopathologic analysis of PF or pleural tissue to establish a diagnosis. Patients usually experience dyspnea, cough, and decreased exercise tolerance at presentation, but an MPE could be first noted as an incidental finding on imaging studies in an asymptomatic patient. Most patients with an MPE due to adenocarcinoma do not have chest pain, whereas 60% of patients with mesothelioma can experience a constant dull or occasionally localized pleuritic chest pain.[13] Patients with an MPE due to sarcoma can present with a pneumothorax.[14] Chest physical findings are typical for pleural effusions; however, extrapleural findings could direct attention toward a previously undiagnosed underlying malignancy. The detection of an effusion coincident with a newly diagnosed cancer does not establish an MPE because 50% of such effusions are nonmalignant.

In some circumstances, establishing the malignant etiology of a pleural effusion might not offer prognostic or therapeutic benefit. A fragile patient with multiple comorbid conditions and an undiagnosed small effusion, for instance, might benefit from observation rather than invasive diagnostic interventions. Conversely, the occurrence of an effusion in a patient with an underlying malignancy should not be assumed to be malignant if the presence of an MPE would alter tumor staging and therapeutic decisions. The presence of an MPE is required to stage a non–small cell lung cancer as IIIB (T4M0). However, it has been recently reported that patients with an MPE but without other evidence of metastatic disease have a median survival of 8 months vs 13 months for patients with other T4M0 disease (stage IIIB) without MPE.[15] This observation underlies recent recommendations from the International Association for the Study of Lung Cancer to classify non–small cell lung cancer with MPE as stage IV disease.[15]

IMAGING

Although standard chest radiographs can detect as little as 50 mL of PF on a lateral view,[16] they provide only suggestive findings for the diagnosis of MPE (Figure 1). A massive effusion increases the probability of a malignant etiology and commonly produces a meniscus sign with fluid tracking up the lateral chest wall, a shift of the mediastinum to the contralateral side, and an inversion of the diaphragm.[17] Radiographic signs of an MPE include circumferential lobulated pleural thickening, crowding of ribs, and elevation of the hemidiaphragm or ipsilateral mediastinal shift consistent with lung atelectasis due to airway obstruction by a tumor (Figure 2).[17]

Chest ultrasonography is increasingly used to evaluate patients with pleural effusions because it detects small



FIGURE 2. Frontal chest radiograph of a 71-year-old man with mesothelioma showing lobulated circumferential right pleural thickening. A mesothelioma was diagnosed by thoracoscopic pleural biopsy.

volumes (5 mL) of fluid,[18] identifies imaging features suggestive of an MPE, and guides thoracentesis and chest-catheter insertion. Findings that suggest MPE include solid pleural densities, hypoechoic pleural thickening with irregular or unclear borders,[19] invasion of pleura-based masses into neighboring structures, and swirling patterns within PF that represent cellular debris.[20] Pleural metastases can appear circular, nodular, hemispheric, or broad based with frond-like extensions into the pleural space (Figure 3).[19]

Contrast-enhanced chest computed tomography (CT) provides the most useful imaging information for evaluating patients with suspected MPE (Figure 1, right). Images that include the upper abdomen allow detection of adrenal and hepatic metastases. An occult primary tumor could be identified in the form of a breast mass (breast cancer), lung nodule (lung cancer), mediastinal mass (thymoma), or airspace consolidation (lymphoma).[17] Performance of CT before large-volume thoracentesis improves diagnostic sensitivity by allowing both the visceral and parietal pleurae to be imaged.

The following chest CT findings suggest MPE: (1) circumferential pleural thickening, (2) nodular pleural thickening, (3) parietal pleural thickening greater than 1 cm, and (4) mediastinal pleural involvement or evidence of a pri-



FIGURE 3. Top left, Frontal chest radiograph showing a moderate-sized right pleural effusion with opacification of the middle and right lower lobes and a left lung metastatic nodule (arrow). Top right, Sagittal ultrasonogram of the lower right side of the chest showing an anechoic effusion (E) with a lobulated echogenic mass along the diaphragmatic pleura (arrows). Bottom left, Image obtained during ultrasonographic biopsy showing biopsy needle (arrows) traversing effusion and entering diaphragmatic mass. Cytologic evaluation confirmed metastatic adenocarcinoma consistent with a renal primary tumor. Bottom right, Image obtained during placement of a guidewire (arrow) for insertion of a 14F catheter for drainage and subsequent talc sclerosis.



FIGURE 4. Contrast-enhanced computed tomogram at the level of the aortopulmonary window of a 67-year-old man with mesothelioma showing lobulated left pleural thickening that extends along the mediastinal pleura (arrowheads). Note the presence of associated calcified left pleural plaques (arrow) reflective of prior asbestos exposure.

mary tumor (Figure 4).[21,22] Each of these findings has a reported specificity of between 22% and 56% and a sensitivity of between 88% and 100%.[21-23] Findings suggestive of a mesothelioma include involvement of interlobar fissures and pleural thickening greater than 1 cm.[22] Coexistence of calcified pleural plaques with diffuse pleural thickening further suggests mesothelioma. If pleural nodularity or thickening are found on preoperative chest CT even in the absence of a pleural effusion, assessment for pleural metastases is warranted before patients undergo resection of lung cancer.[24] Chest CT can help determine the etiology of a paraneoplastic pleural effusion by revealing tumor involvement of thoracic structures, such as the superior vena cava (Figure 5).

Magnetic resonance imaging (MRI) provides better imaging of soft tissues than chest CT and can detect tumor invasion into the chest wall and diaphragm.[25] Magnetic resonance imaging with triple-echo pulse sequences is highly sensitive for small effusions and can identify features of fluid that differentiate exudative from transudative effusions.[26] In addition, MRI has a sensitivity and specificity similar or superior to chest CT for diagnosing pleural malignancies when CT criteria for malignant pleural disease are used in combination with MRI signal intensity findings (Figure 6).[17,27-30] Despite these favorable features, chest MRI is reserved for more complex pleural effusions because MRI is not as effective as contrast CT for imaging the lung parenchyma.

Chest imaging with positron emission tomography (PET) with fluorine 18–labeled fluorodeoxyglucose (FDG) has a reported sensitivity for malignant pleural disease of 93% to 100%, negative predictive value of 94% to 100%, specificity of 67% to 89%, and positive predictive value of 63% to 94%.[31-33] False-positive results occur in patients with uremic pleuritis, parapneumonic effusions, and other inflammatory pleural conditions that include posttreatment with talc instillation for pleurodesis.[34] Particularly when PF cytology is negative, negative PET-FDG results provide the most useful clinical information for ruling out an MPE.

Fused images can be created by combining PET-FDG and CT, allowing improved localization of PET-detected abnormal FDG activity for guiding biopsy (Figure 7).[35] In a series of 31 patients, Toaff et al[36] reported that the presence of focal increased FDG activity in the pleural space combined with CT detection of a concomitant solid pleural density had a sensitivity of 95%, a specificity of 80%, a positive predictive value of 91%, a negative predictive value of 89%, and an accuracy of 90% for malignant pleural disease.[36] Combined PET-CT imaging can also be used to differentiate increased FDG activity due to talc pleurodesis from intrapleural tumor recurrence by detecting pleu-



FIGURE 5. Left, Frontal chest radiograph of a 62-year-old woman with superior vena cava syndrome showing a right upper lobe nodule (large arrow) with a right hilar/mediastinal mass (small arrow) and a right transudative pleural effusion (asterisk). Middle, Contrast-enhanced computed tomogram at the level of the aortic arch revealing a right upper lobe mass confirmed by transthoracic biopsy as a non–small cell carcinoma. Right, Contrast-enhanced computed tomogram showing a right mediastinal and hilar mass that occludes the superior vena cava. Note the mediastinal and left chest wall venous collaterals and edema of the subcutaneous fat resulting from superior vena cava occlusion.



FIGURE 6. Left, Contrast-enhanced computed tomogram at the level of the left atrium shows a right pleural effusion with foci of pleural nodularity (large arrows) and thickening (small arrows). Right, Coronal gradient-echo magnetic resonance imaging obtained after gadolinium administration showing irregular pleural enhancement involving the mediastinal, costal, and diaphragmatic pleural surfaces (arrows) diagnosed by thoracoscopic biopsy as mesothelioma.

ral thickening (characteristic of talc pleurodesis) with increased CT attenuation.[34,37]

PLEURAL FLUID ANALYSIS

Despite the improved diagnostic accuracy of new chest-imaging modalities, cytologic or tissue biopsy confirmation is required to establish a diagnosis of MPE. Most patients who present with undiagnosed pleural effusions benefit from thoracentesis. Although 15% of patients who present with non–small cell lung cancer have an MPE,[38] bronchoscopy has a low diagnostic yield in evaluating patients for possible MPE if evidence of a pulmonary parenchymal or airway lesion is lacking.[39,40]

The selection of a site for thoracentesis has traditionally been guided by chest radiographic and physical findings.[41] However, recent studies show that chest ultrasonographic guidance improves the appropriateness of needle-insertion–site selection[42]; some experts recommend the routine use of ultrasonographic guidance for thoracentesis.[42-45]

Certain characteristics of PF can signal an increased likelihood of MPE and can guide decisions for further diagnostic studies. For example, an exudative effusion has a higher probability of being malignant than a transudative effusion; however, the finding is nonspecific because of the multiple inflammatory causes of exudative effusions. It should be noted that 3% to 10% of MPEs are transudates.[46,47] Malignant transudative effusions result from the imperfect application of diagnostic rules that categorize pleural effusions or comorbid conditions associated with transudates, such as hypoalbuminemia, cirrhosis with ascites, or chronic heart failure.



FIGURE 7. Left, Frontal chest radiograph showing a left pleural effusion. Middle, Fused axial positron emission tomogram/computed tomogram showing a right pleural effusion and irregular thickening of the left pleural surface with a focal area of increased metabolic activity (thin arrow) and calcified left pleural plaques (thick arrows). Right, Image obtained during computed tomography–guided biopsy showing a cutting needle within the area of focal increased metabolic activity seen in Figure 7, middle. Metastatic adenocarcinoma was revealed on biopsy.

TABLE 1. **Criteria-Based Rules to Identify Exudative Pleural Effusions***

Rule†	PF/S LDH >0.6	PF/S protein >0.5 PF	LDH >67% serum normal	PF cholesterol >45 mg/dL	PF protein >3 g/dL
Light criteria	X	X	X		
Abbreviated Light criteria		X	X		
2-Criteria rule without need for blood test			X	X	
3-Criteria rule without need for blood test			X	X	X

*LDH = lactate dehydrogenase; PF= pleural fluid; S = serum.
†Fulfillment of any 1 criterion defines an exudative effusion. X denotes that a criterion is used in the rule.

Light Criteria

Pleural effusions are most commonly categorized as transudates or exudates by the diagnostic rule termed Light criteria (Table 1). This rule defines an exudate if any 1 of the 3 criteria are met. Light criteria have an overall diagnostic accuracy of 93% but commonly misclassify effusions (approximate diagnostic accuracy, 65%) when any 1 of the 3 criteria has a value near its cutoff point.[48] Moreover, a meta-analysis of studies that evaluated Light criteria showed that the 2 criteria that incorporate serum lactate dehydrogenase (LDH) values (PF LDH and PF-to–serum LDH ratio) have a high coefficient of correlation, as would be expected by mathematical coupling.[49] Consequently, either of the 2 LDH criteria can be removed from the Light rule without affecting its overall diagnostic performance. This 2-criteria rule has been termed the "abbreviated Light criteria."[49]

Light criteria can be effectively used to categorize effusions as exudates because they are associated with the increased permeability of pleural membranes or the breakdown of intrapleural cells, allowing high–molecular-weight constituents to concentrate in the pleural space. Therefore, other PF tests that measure high–molecular-weight compounds would be expected to be similarly useful for categorizing effusions as exudates. Confirming this expectation, a meta-analysis found that the monitoring of PF cholesterol or albumin was as effective as Light criteria in categorizing an effusion as an exudate.[49] Unlike Light criteria, the proposed 2- and 3-criteria rules that use PF protein, cholesterol, and LDH levels do not require concomitant blood tests (Table 1). As with all diagnostic rules that combine different tests in "or" rules, the 3-test combination has a higher sensitivity but a lower specificity than the 2-test rule. Other characteristics of PF can suggest the presence of an MPE (Table 2), but none has sufficient diagnostic accuracy to obviate cytopathologic confirmation.

TABLE 2. **Pleural Fluid Findings Suggestive of Malignant Pleural Effusion (MPE)**

Cell counts	
Lymphocytes	More than 50% of MPEs have lymphocyte-predominant effusions (lymphocytes = 50%-70% of nucleated cells). Lymphocyte counts >85% suggest tuberculous pleurisy, lymphoma, sarcoidosis, chronic rheumatoid pleurisy, yellow-nail syndrome, or chylothorax
Erythrocytes	Bloody effusions common with MPE but also found with benign asbestos pleurisy, postcardiac injury syndrome, trauma, and pulmonary infarction
Eosinophils	From 12%-24% of eosinophilic effusions (>10% eosinophils) are malignant in etiology[50-52]
Chemical analysis	
Protein and LDH	Most MPEs are exudates according to Light criteria; 3%-10% are transudates.[46,47] LDH >1000 IU/L narrows the differential diagnosis to MPE, empyema, rheumatoid pleurisy, and pleural paragonimiasis
Amylase	1%-8% of pleural effusions are rich in amylase (>100 IU/L)[53,54] and so routine amylase measurement is not cost-effective unless pancreatic disease or ruptured esophagus is strongly suspected before the test.[53] Higher pleural fluid concentrations are associated with shorter survival times among patients with MPE[54]
pH	Levels <7.30 in 30% of MPE cases[55-57]; decreasing pleural fluid pH correlates with decreasing survival and success rates with pleurodesis[55-58]; however, in the absence of other clinical information, the correlation does not assist patient selection for pleurodesis[7,59,60]
Glucose	Levels <60 mg/dL suggest MPE, rheumatoid pleurisy, complicated parapneumonic effusion, tuberculous pleurisy, lupus pleuritis, or esophageal rupture

Cytology

Standard PF cytology can provide confirmation of an MPE but has a diagnostic yield of only 65% in general categories of patients with MPE.[61-66] The reported diagnostic yield for lymphomatous MPE ranges from 22% to 94%.[9] The diagnostic yield could increase with repeated thoracenteses[66,67] but not with the submission of larger volumes of PF for cytologic analysis.[65] Positive results on standard cytology might not differentiate between pleural adenocarcinoma and mesotheliomas or between lymphomas and reactive lymphocytosis without special studies.

Additional PF studies could complement standard cytology. Electrochemiluminescence and microparticle enzyme immunoassays of PF can detect tumor markers, such as carcinoembryonic antigen, carbohydrate antigen 15-3, cytokeratin 19 fragments, and cancer antigen 125. Unfor-

tunately, none of the available tumor markers has sufficient diagnostic yield to be used in routine clinical practice. Combinations of tumor markers, however, could help select patients with negative PF cytologic results for additional diagnostic studies.[68-70] Groups of immunohistochemical markers could lead to a diagnosis in approximately 80% of patients with malignant mesothelioma.[71,72]

Genetic analysis of PF offers opportunities to improve the sensitivity of thoracentesis for MPE.[63,64,73,74] Common features of early malignancy, which include DNA methylation and other genetic mutations and microsatellite alterations, can be detected by polymerase chain reaction (PCR) and microarray techniques that measure simultaneously the expression of thousands of genes in a single sample. In a study of 31 patients with various pleural effusions, DNA methylation was observed in 59% of PF samples from patients with MPEs but in none of the benign effusions.[74] The addition of DNA methylation raised the sensitivity of cytology alone from 63% to 88%. Another study confirmed this finding, establishing the promise of PF epigenetic analysis as a rapid and reliable test when combined with standard cytology.[64]

Holloway et al[75] suggest that PF gene-expression tests can establish the cancer cell type and estimate the likely response to cancer therapy. Using a real-time PCR–based assay of 17 genes, they differentiated between biopsy-proven malignant mesothelioma and lung adenocarcinoma.[75] Detection of epidermal growth factor receptor (EGFR) mutations in malignant PF cells can predict a favorable response to gefitinib therapy in patients with non–small cell lung cancer.[76] However, absence of EGFR mutations does not preclude a therapeutic response.[77] Detection of Kristen ras oncogene mutations is a negative predictor of responsiveness to EGFR tyrosine kinase inhibitors.[78] Elevated levels of serum mesothelin-related protein (SMRP) are found in 84% of patients with malignant mesothelioma, but in fewer than 2% of patients with lung cancer,[79] making them a promising marker for the diagnosis of mesothelioma. They can also be used to clinically monitor patients with mesothelioma and to determine their prognosis. For the differentiation of mesothelioma from lung cancer controls, the area under the receiver operating curve for serum SMRP is 0.77 (95% confidence interval, 0.71-0.83), with a best cutoff of 1.00 nmol/L (sensitivity, 68.2%; specificity, 80.5%).[80] Other promising markers and combinations of markers have been recently reported and reviewed.[79,81-83]

Accessible techniques for detecting aneuploidy in PF samples, such as fluorescence in situ hybridization analysis, image analysis cytometry, and PCR, are more sensitive than standard cytologic studies.[84] Investigations are under way to determine if the detection of aneuploidy adds diagnostic value and meaningful therapeutic consequences to standard PF analysis for the detection of MPE.[84,85] Evidence to date suggests that detection of aneuploidy is a useful marker for identifying malignant cells[85,86] and that genetic changes often precede morphologic changes in a developing malignancy.[86]

Lymphomatous MPEs present a special diagnostic challenge. It can be difficult to classify the subtype of lymphoma and to differentiate between lymphoma and small round-cell tumors or reactive lymphocytosis. Lymphoma subtypes commonly associated with MPEs include lymphoblastic lymphoma; follicular center cell lymphoma, including Burkitt-type lymphoma; splenic marginal zone lymphoma; mucosa-associated lymphoid tissue lymphoma; and anaplastic large-cell lymphoma. Experienced cytology laboratories can use various immunologic and molecular cytogenetic tests in combination with morphologic examination to establish the presence of a lymphomatous pleural effusion with a 100% sensitivity and specificity and to determine the lymphoma subtype.[9]

Pleural Biopsy

When an MPE is still suspected after thoracentesis and PF analysis but cytology has not established a specific diagnosis, pleural biopsy might be indicated. Image-guided and thoracoscopic biopsy techniques have improved diagnostic yield as compared with traditional closed pleural biopsy using Abrams or Cope needles. The specificity of closed-needle biopsy for MPE is high, but case series report sensitivities that range from 7% to 72%.[40,62,87-90] The most recent case series reported a sensitivity for mesothelioma of 31% and for adenocarcinoma of 69% when adequate tissue was acquired[40]; adequate tissue is obtained in 71% to 91% of closed-needle biopsy specimens.[91,92] However, it should be noted that closed pleural biopsy leads to a diagnosis in only 7% of patients with preexisting negative PF cytologic study results.[62] Only 3 to 4 biopsy samples are necessary to achieve maximal sensitivity with closed-needle biopsy.[40,93]

At most centers, closed-needle biopsy has been supplanted by ultrasonography or chest CT–guided percutaneous pleural biopsy.[90,94,95] Diacon et al[42] reported an 86% sensitivity and a 100% specificity with transthoracic ultrasonography–guided biopsy when they used a 14-gauge cutting needle for pleura-based lesions 20 mm or greater in diameter. Maskell et al[90] reported the results of a randomized study comparing closed pleural biopsy with CT-guided needle biopsy in patients with negative cytologic results for MPE. They observed higher diagnostic yields with CT-guided vs closed pleural biopsy, with sensitivities of 87% vs 47%, specificities of 100% vs 100%, positive predictive values of 100% vs 100%, and negative predictive values of 80% vs 44%, respectively. Many patients in

the CT-guided group had minimal (5 mm) pleural thickening that was successfully biopsied.

Although some centers perform thoracoscopic pleural biopsy after a nondiagnostic cytologic analysis of exudative PF, most would first do image-guided pleural biopsy if a region of pleural thickening or a mass were detected. Available thoracoscopic techniques include video-assisted thoracoscopic surgery (VATS)[96] and medical thoracoscopy with either a rigid thoracoscope[97] or a semirigid pleuroscope.[98,99] A wide-field examination of the pleural space is possible with VATS, and large tissue-biopsy samples can be obtained. However, VATS requires general anesthesia and an induced pneumothorax, which might not be tolerated by some patients with impaired lung function. Medical thoracoscopy is performed without pneumothorax under moderate sedation, making it easier for patients with limited pulmonary reserves to tolerate. Pulmonary physicians skilled in bronchoscopy should find the semirigid pleuroscope easy to use because it has the same light source, video equipment, and manual controls as the fiberoptic bronchoscope.[98,99]

Thoracoscopy has a 90% to 100% sensitivity for MPE.[100,101] In some patients, studding of pleural surfaces with tumor can be subtle, or coexisting benign lesions could misdirect biopsy sampling. For such patients, techniques that cause metastases to fluoresce can guide biopsy sampling.[102,103]

For diagnosis of mesothelioma and classification of its subtype, a large pleural biopsy specimen is often necessary. Immunohistochemical staining provides essential information in the diagnostic evaluation.[72] Some specimens could require electron microscopy to differentiate mesotheliomas from adenocarcinomas or fibrous pleuritis.[72] Mesothelioma subtype classification becomes important in centers that recommend aggressive trimodality therapy with extrapleural pneumonectomy for the epithelial but not the mixed or sarcomatoid subtypes. When this is a consideration, patients with suspected mesothelioma could be referred for open pleural biopsy by a limited thoracotomy, which has a sensitivity for epithelial malignant mesothelioma of 97% and specificity of 56%.[104] As many as 44% of patients who receive a pathologic diagnosis of nonepithelial subtype at resection could have been misdiagnosed initially with the epithelial subtype by more limited biopsy techniques.[104]

Despite the high diagnostic yield of thoracoscopy for MPEs, it is less effective in providing a specific diagnosis for nonmalignant pleural disease, leading to a diagnosis in only 50% of patients with unexplained exudative pleural effusions.[105] Therefore, referral of patients for thoracoscopy should be guided by the pretest probability that an exudative effusion is malignant. In a multivariate analysis, Ferrer et al[105] examined clinical predictors of MPE and derived a prediction rule of 4 variables: symptoms lasting longer than 1 month, absence of fever, blood-tinged PF, and chest CT findings suggestive of malignancy. Among 93 patients referred for VATS, 100% of the 28 patients fulfilling all 4 criteria had an MPE, 74% of those fulfilling 3 criteria, 24% of those fulfilling 2 criteria, and none of those fulfilling 0 or 1 criterion.[105]

MANAGEMENT OF MPEs

Because management of MPEs is palliative and does not improve survival, most physicians wait for symptoms or functional limitations related to the MPE to occur before intervening. However, some centers recommend early interventions at first diagnosis of an MPE to prevent pleural loculations that complicate management. Interventions are directed toward removing PF and, when appropriate, performing pleurodesis or initiating long-term drainage to prevent fluid reaccumulation.

Therapeutic Thoracentesis

Management of symptomatic MPE begins with therapeutic thoracentesis, which assesses the response of dyspnea to fluid removal. If symptoms do not improve with large-volume thoracentesis, alternative causes of dyspnea require evaluation, such as microtumor emboli, lymphangitic cancer, or effects of chemotherapy and radiation therapy. The removal of large volumes of PF could rapidly expand atelectatic lung regions beyond their capacity to reinflate and cause alveolar capillary injury resulting in reexpansion pulmonary edema.[106] It has been recommended that intrapleural pressure be monitored during thoracentesis and the procedure discontinued when pleural pressures reach a threshold pressure.[107] These recommendations, however, have not been subjected to prospective study, and many physicians are not trained in intrapleural pressure monitoring. Feller-Kopman et al[108] recently showed that patients' symptoms during thoracentesis correlated with intrapleural pressure and could serve as an indicator of the safe limits of PF removal. They observed that reexpansion pulmonary edema and excessively negative intrapleural pressures can be avoided if thoracentesis is discontinued when patients experience nonspecific chest discomfort.

Although symptoms can improve after thoracentesis, 98% to 100% of patients with MPE experience reaccumulation of fluid and recurrence of symptoms within 30 days.[109,110] Repeated thoracenteses, therefore, should be reserved for patients who (1) reaccumulate pleural effusions slowly after each thoracentesis, (2) have cancers that commonly respond to therapy with resolution of the associated effusions, (3) appear unlikely to survive beyond 1 to 3 months, and (4) cannot tolerate other more interventional procedures to control pleural fluid, such as pleurodesis.[101,111]

For all other patients, pleurodesis or long-term indwelling catheter drainage is recommended.

Before referring patients for pleurodesis, clinicians should assess their suitability for the procedure using a checklist of questions (Table 3), paying special attention to any causes of dyspnea other than the MPE itself (Table 4). Perhaps the most difficult of the questions to answer concerns the estimated survival after pleurodesis. Most physicians consider an expected survival beyond 2 to 3 months necessary to justify the cost, risks, and discomforts of pleurodesis. Multiple clinical factors have been used to estimate survival, including the cell type and stage of the tumor, characteristics of PF, and performance level. Unfortunately, despite careful patient selection at expert centers, up to 32% of patients do not survive 30 days after pleurodesis,[112-116] highlighting the limited ability of physicians to predict survival for patients with MPE. The American Thoracic Society/European Respiratory Society guideline for MPE management recommends that pleurodesis be limited to patients with PF pH values greater than 7.30[111] because of the direct correlation between low PF pH and poor short-term survival.[56,57] Unfortunately, meta-analyses of pH demonstrate poor predictive performance of PF pH for individual patients.[7,60] Among the criteria now in common use, performance status has the most value for estimating postpleurodesis survival.[117]

Pleurodesis should be restricted to patients who have a reasonable likelihood of responding to the procedure. Successful pleurodesis requires apposition of the visceral and parietal pleurae.[118] Patients with airway obstruction from an endobronchial tumor, extensive intrapleural tumor masses, or multiple pleural loculations resulting in trapped lungs are unlikely to respond. Up to 30% of patients who are evaluated for pleurodesis are unsuitable candidates because of trapped lungs.[115] A number of factors should be considered in estimating the likelihood that a patient will respond to pleurodesis. When a chest radiograph after thoracentesis reveals a distribution of intrapleural air that corresponds with the distribution of PF before thoracentesis, a pneumothorax could suggest a trapped lung (Figure 8).[119-121] Such pneumothoraces usually result from trapped lungs that cannot reexpand during thoracentesis and from the entry of air into the pleural space (as negative intrapleural pressure) along the thoracentesis needle track during fluid removal.

Other signs of poor lung expandability include deviation of the trachea toward the side of the MPE noted on a standard radiograph and evidence on chest CT of loculations, thickened visceral pleural membranes, and large intrapleural tumor masses. The generation of extremely low intrapleural pressures during thoracentesis suggests nonexpandable lung[43,122]; however, the predictive performance of pleural manometry has not been established. The American Thoracic Society/European Respiratory Society guideline for MPE recommends use of PF pH as a predictor of pleurodesis outcome, with decreasing pH corresponding to lower probabilities of response.[111] However, a meta-analysis of primary data from multiple case series found that more than 50% of patients with low PF pH values had improved symptoms after pleurodesis.[59] Moreover, in a randomized trial of thoracoscopic vs chest-tube pleurodesis, Crnjac et al[123] observed that more than 50% of patients with low pH effusions had successful pleurodeses. Pleural fluid pH appears to have no value for selecting patients for pleurodesis.

TABLE 3. **Questions to Guide Selection of Patients for Pleurodesis**

Is the underlying tumor and resulting malignant pleural effusion responsive to chemotherapy or radiotherapy?
Are the patient's respiratory symptoms caused by the effusion?
Does the patient's dyspnea improve after therapeutic thoracentesis?
Do alternative causes of dyspnea exist that will not respond to pleurodesis?
Does the patient's life expectancy warrant pleurodesis (eg, is it longer than 2-3 months)?
Will pleurodesis resolve the effusion and sufficiently improve the patient's symptoms?
Does the lung expand to the chest wall after therapeutic thoracentesis?
Do imaging studies suggest multiloculated effusions and thick visceral pleural membranes suggestive of a trapped lung?
Will the amount of intrapleural tumor prevent an effective pleurodesis?
Do imaging studies detect large tumor masses along pleural surfaces?

TABLE 4. **Causes of Dyspnea in Patients With Malignant Pleural Effusions**

Pleural
Malignant effusions
Effusions caused by
Drugs
Pneumonia
Heart failure
Pulmonary embolism
Pulmonary parenchyma
Lymphangitic cancer
Chemotherapy-induced pneumonitis or fibrosis
Radiation fibrosis or pneumonitis
Extensive tumor mass with lung restriction
Airways
Airway obstruction by tumor
Bilateral vocal cord paralysis from recurrent laryngeal nerve praxis
Cardiac and pericardial
Chronic heart failure
Pericardial effusion
Constrictive pericarditis
Restrictive cardiomyopathy due to tumor infiltration
Vascular
Pulmonary thromboemboli
Tumor emboli
Other
Deconditioning
Poor nutrition
Cancer-related cachexia
Myopathy
Chest wall invasion by tumor
Progression of underlying lung disease (eg, emphysema)



FIGURE 8. Left, Frontal chest radiograph of a 67-year-old woman with a malignant left pleural effusion showing opacification of the left hemithorax with contralateral shift of the mediastinum. Right, Chest radiograph after pigtail catheter placement for planned pleurodesis showing a left hydropneumothorax with persistently collapsed left upper and lower lobes. Note the thickening of the visceral pleural surface (arrows). Because the configuration of the hydrothorax established a trapped lung, the catheter was subsequently removed, and pleurodesis was not attempted.

Little consensus exists as to the ideal procedure for pleurodesis. A survey of physicians in 5 English-speaking countries showed substantial differences in the pleurodesis procedures used in each country.[124] That variability could be due in part to physician dissatisfaction with available techniques, all of which have their shortcomings.

Existing pleurodesis methods include instillation of compounds via an intrapleural chest catheter or various techniques with the use of thoracoscopy. In the traditional approach to chest-catheter pleurodesis, a short-term catheter is inserted for drainage of PF and for instillation of a sclerosing agent and then removed when minimal fluid remains to be drained. Most centers no longer use conventional large-bore (20F-32F) chest tubes because of the equivalent effectiveness of sm all-bore (9F-14F) catheters,[125-131] which provide opportunities for outpatient pleurodesis.[132] Each of the several protocols that exist for chest-catheter pleurodesis are based on empiric experience and limited comparative studies. Most experts recommend that the sclerosant be instilled only when catheter drainage has decreased to less than 150 mL/d and that the chest catheter be removed after sclerosant instillation when drainage returns to less than 150 mL/day, which usually requires multiple days of hospitalization.

Recently, studies have reported the outcomes of accelerated pleurodesis protocols.[131,133-135] Yildirim et al[134] randomized patients to a standard protocol that required diminished PF drainage vs a protocol that instilled sclerosant immediately after catheter insertion. The success rate for pleurodesis did not differ between the 2 groups, but those following the accelerated protocol had shorter hospital stays. In a randomized controlled trial, Goodman and Davies[133] observed similar pleurodesis success rates when chest catheters were removed 24 hours vs 72 hours after instillation of talc slurry. In an observational study, Sartori et al[131] reported a high rate of success with pleurodesis when small-bore catheters were inserted with ultrasonographic guidance to ensure proper positioning and when serial ultrasonography was used to ensure that the pleural space was free of fluid before instillation of the sclerosant (Figure 3). Ultrasonography-directed thoracenteses were also performed intermittently to drain reaccumulating or loculated PF; catheters were removed when less than 100 mL of catheter drainage occurred during any 12-hour period. Marom et al[136] similarly demonstrated the value of ultrasonographic guidance in chest-catheter insertion. Spiegler et al[135] reported a 79% success rate with pleurodesis when the sclerosant was instilled as soon as 2 hours after catheter insertion with routine catheter removal 2 hours after instillation of the sclerosing agent.[135] Hospital stays could be shortened or even avoided with the use of tunneled pleural catheters[137] or portacath catheters.[138,139] These catheters can be inserted in an outpatient setting, allowing patients to return for instillation of a sclerosant if a spontaneous pleurodesis does not occur after 2 weeks of home drainage.

Sclerosants can cause acute pleuritis and pleuritic chest pain. Instillation of lidocaine through the chest catheter has been proposed to prevent pain but no evidence of efficacy exists.[140] One study reported good pain control with lidocaine spray administered before talc insufflation.[141] No evidence exists that patients should be rotated through 4 quadrant positions to ensure wide dispersal of the sclerosant in the pleural space.[142-144] Observational studies and animal investigations have shown that systemic corticosteroids lower the rate of successful pleurodesis and should be avoided.[101,145-148] The effects of nonsteroidal anti-inflammatory agents on pleurodesis have not been investigated in

humans; however, ketoprofen has been shown not to hinder pleurodesis in a rabbit model.[149] Minimal data support the role of intrapleural instillation of fibrinolytic agents for patients with loculations whose lungs do not reexpand after chest-catheter insertion.[150]

Controversy exists regarding the ideal sclerosant for chest-catheter pleurodesis (Table 5). Because of the absence of adequate comparative trials of different agents, extensive practice variation exists.[124] A Cochrane Review[188] and another recent systematic review of the literature[144] concluded that talc had the highest efficacy for preventing MPE recurrence when compared with other commonly used sclerosants; most contemporary studies report a 71% to 96% success rate with talc instilled through a chest-catheter tube.[115,136,142,153,160,163,189,190] Talc could cause pleurodesis by promoting angiogenesis[191] and stimulating mesothelial cells to release basic fibroblast growth factor, interleukin 8, vascular endothelial growth factor, transforming growth factor, and other proinflammatory mediators that stimulate pleural fibrosis.[192,193]

Adverse effects of talc include dyspnea, fever, chest pain, atelectasis, pneumonia, arrhythmias, empyema, and acute respiratory failure.[115,194-196] Up to 16% of patients develop transient unilateral interstitial infiltrates ipsilateral to the side of pleurodesis.[197] Respiratory failure, which could progress to acute respiratory distress syndrome, occurs with equal frequency after talc administration by slurry (chest catheter) or insufflation (thoracoscopy). The small particle size of talc allows its systemic absorption and wide circulation to vascular beds distant from the pleural space, promoting tissue inflammation.[198,199] Different sources of talc vary in particle size, perhaps explaining why centers using larger talc particles for pleurodesis rarely observe acute respiratory failure,[200-203] whereas those that use smaller, noncalibrated talc report a 4% to 8% incidence of respiratory failure and a 30% incidence of severe hypoxemia.[115,204] Experts now recommend the use of talc calibrated to a mean particle size of less than 20 microns with no particles less than 10 microns. Other investigational and available sclerosants (Table 5) have not been compared with talc in large randomized trials, and so little information is available on their toxicity.

TABLE 5. **Available and Investigational Sclerosing Agents for Pleurodesis**

Agent	Reported success rates* (%)
Mineral	
Talc	70-100 [115,144,151-157]
Antibiotic	
Doxycycline	60-81 [158-160]
Quinacrine	64-100 [161-165]
Antiseptic	
Iodopovidone	64-96 [166-170]
Silver nitrate	96 [153]
Anticancer drug	
Bleomycin	64-84 [148,156,171,172]
Mitoxantrone	76-88 [173-175]
Cisplatin	65-83 [176,177]
Bacterial product or component	
Corynebacterium parvum	65-92 [178-182]
Staphylococcus aureus superantigen	100 [183]
OK432	53-79 [176,184,185]
Cytokine	
Interferon alpha-2β	62-100 [171,186,187]

*Success rates variably reported as rate immediately after pleurodesis or rate obtained at different time points after pleurodesis.

Thoracoscopic Pleurodesis

Various thoracoscopic procedures produce pleurodesis by intrapleural instillation of sclerosants or generation of pleural injury by dry-gauze abrasion or other physical techniques. Available instruments include video-assisted thoracoscopes, medical thoracoscopes, and pleuroscopes.[98,99,205] Video-assisted thoracoscopes allow wide access to the pleural space, making possible the lysis of extensive loculations and adhesions for patients who would otherwise not benefit from pleurodesis. Disadvantages include cost and the need for general anesthesia and induced pneumothorax, which some patients with compromised lung function might not tolerate. However, the performance of VATS without general anesthesia has been recently reported.[206] Medical thoracoscopy and pleuroscopy are usually done with local anesthesia and moderate sedation. Thoracoscopy produces effective pleurodesis in 71% to 97% of patients[115,151,152,154,189,207-210] with a morbidity rate of 3% to 26% and a mortality rate of less than 1%.[123,154,208,210]

Thoracoscopic vs Chest-Catheter Pleurodesis

No large-scale appropriately randomized studies have compared the efficacy of pleurodesis by chest-catheter instillation of sclerosants vs various thoracoscopic techniques in patients with MPE. A recent Cochrane systematic review of 2 studies that treated 112 patients with talc by either chest catheter or thoracoscopy reported slightly better outcomes with thoracoscopy (relative risk of nonrecurrence, 1.19; 95% confidence interval, 1.04-1.36).[188] Although this difference was not supported by a subsequent randomized trial of talc pleurodesis by chest catheter or thoracoscopy, subgroups of patients with underlying lung or breast cancer had better outcomes with thoracoscopy.[115] Crnjac et al[123] observed similar outcomes for thoracoscopy with mechanical pleural abrasion vs chest-catheter pleurodesis with talc slurry; at pH values less than 7.30, better outcomes were observed with thoracoscopy (81% vs 55%). Low pH can be used to identify patients with extensive intrapleural loculations and adhesions that can be lysed by thoracoscopy, perhaps explaining this observed difference.

In the absence of high-quality comparative outcome studies, the available institutional expertise with the various pleurodesis techniques and observed clinical outcomes should determine the local approach to pleurodesis. Some patient-related factors, however, are important to consider. Patients with clinical, radiographic, or ultrasonographic signs of extensive pleural tumor and trapped lung are more likely to respond to pleurodesis by thoracoscopy, which can lyse adhesions or, if lung reexpansion and a successful pleurodesis appear unlikely, indicate that drainage via a long-term indwelling catheter is required.[113] At most centers, patients are referred for chest-tube pleurodesis because of its high success rate, low cost, and low morbidity.[152] Wider adoption of small-bore, tunneled catheters for pleurodesis could further support the use of chest-catheter pleurodesis.

Drainage via Long-Term Indwelling Catheter

Long-term indwelling catheters placed with or without ultrasonographic guidance allow intermittent drainage of up to 1000 mL of PF 2 to 3 times a week for prolonged periods.[211-217] Immediate relief of dyspnea occurs in 94% to 100% of patients,[213-216] persistent relief for 30 days in 90%.[213] Patients tolerate the procedure well with close follow-up for complications of catheter infection, insertion-site skin breakdown, cellulitis, catheter obstruction with tension pleural effusion, empyema, and tumor spread along the catheter track.[212,214,215,218,219]

Several studies report that spontaneous pleurodesis occurs in 40% to 58% of patients with long-term indwelling catheters after 2 to 6 weeks of drainage.[214,216] After several weeks of drainage, sclerosants can be instilled through the catheter if spontaneous pleurodesis does not occur.[213] In a randomized trial, Putnam et al[220] showed equivalent symptom control with long-term indwelling catheters and pleurodesis with doxycycline instillation through a chest tube. Because of the high rate of "spontaneous" pleurodesis and the ability to later instill sclerosants, some experts recommend long-term indwelling catheters as primary MPE therapy for patients who can manage home drainage.[137] Additional prospective studies are needed to compare the cost of drainage using long-term indwelling catheters as primary therapy vs thoracoscopy and inpatient chest-catheter pleurodesis and to assess patients' attitudes toward and outcomes with these procedures.

PLEUROPERITONEAL SHUNTING

Among patients who cannot undergo or do not benefit from pleurodesis, those who can manage long-term indwelling catheter drainage at home could benefit from pleuroperitoneal shunting.[113,221-223] Symptoms subside in 95% of treated patients; complications occur in 15%.[222] Paraneoplastic chylous effusions could also respond to shunting.[224] Shunt complications occur in 15% of patients in the form of skin erosion, infection, and shunt occlusion that requires shunt revision or replacement.[222]

CONCLUSION

Considerable advances have been made in the diagnosis of MPEs through specialized cytologic and imaging studies along with improved methods for pleural biopsy. Although multiple, well-tolerated techniques exist to control MPEs by pleurodesis or long-term catheter drainage, all management approaches remain palliative. In selecting an appropriate intervention, clinicians should consider local expertise, the patient's clinical status, and comparative institutional outcomes from the available techniques.

REFERENCES

1. Henschke CI, Yankelevitz DF, Davis SD. Pleural diseases: multimodality imaging and clinical management. *Curr Probl Diagn Radiol.* 1991; 20(5):155-181.
2. Storey DD, Dines DE, Coles DT. Pleural effusion: a diagnostic dilemma. *JAMA.* 1976;236(19):2183-2186.
3. Martinez-Moragon E, Aparicio J, Sanchis J, Menendez R, Cruz Rogado M, Sanchis F. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. *Respiration.* 1998;65(2):108-113.
4. Hausheer FH, Yarbro JW. Diagnosis and treatment of malignant pleural effusion. *Cancer Metastasis Rev.* 1987;6(1):23-40.
5. Awasthi A, Gupta N, Srinivasan R, Nijhawan R, Rajwanshi A. Cytopathological spectrum of unusual malignant pleural effusions at a tertiary care centre in north India. *Cytopathology.* 2007;18(1):28-32.
6. Ismail-Khan R, Robinson LA, Williams CC Jr, Garrett CR, Bepler G, Simon GR. Malignant pleural mesothelioma: a comprehensive review. *Cancer Control.* 2006;13(4):255-263.
7. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. *Chest.* 2000;117(1):79-86.
8. Boulanger E, Gerard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. *J Clin Oncol.* 2005;23(19):4372-4380.
9. Das DK. Serous effusions in malignant lymphomas: a review. *Diagn Cytopathol.* 2006;34(5):335-347.
10. Rice TW, Rodriguez RM, Barnette R, Light RW. Prevalence and characteristics of pleural effusions in superior vena cava syndrome. *Respirology.* 2006;11(3):299-305.
11. Sahn SA. State of the art: the pleura. *Am Rev Resp Dis.* 1988;138(1): 184-234.
12. Asakura H, Togami T, Mitani M, et al. Usefulness of FDG-PET imaging for the radiotherapy treatment planning of pyothorax-associated lymphoma. *Ann Nucl Med.* 2005;19(8):725-728.
13. Lee YC, Light RW, Musk AW. Management of malignant pleural mesothelioma: a critical review. *Curr Opin Pulm Med.* 2000;6(4):267-274.
14. Chen W, Shih CS, Wang YT, Tseng GC, Hsu WH. Angiosarcoma with pulmonary metastasis presenting with spontaneous bilateral pneumothorax in an elderly man. *J Formos Med Assoc.* 2006;105(3):238-241.
15. Postmus PE, Brambilla E, Chansky K, et al, International Association for the Study of Lung Cancer International Staging Committee, Cancer Research and Biostatistics, Observers to the Committee, Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. *J Thorac Oncol.* 2007;2(8):686-693.
16. Blackmore CC, Black WC, Dallas RV, Crow HC. Pleural fluid volume estimation: a chest radiograph prediction rule. *Acad Radiol.* 1996;3(2):103-109.
17. Qureshi NR, Gleeson FV. Imaging of pleural disease. *Clin Chest Med.* 2006;27(2):193-213.
18. Kocijancic I, Vidmar K, Ivanovi-Herceg Z. Chest sonography versus lateral decubitus radiography in the diagnosis of small pleural effusions. *J Clin Ultrasound.* 2003;31(2):69-74.

19. Mayo PH, Doelken P. Pleural ultrasonography. *Clin Chest Med*. 2006; 27(2):215-227.

20. Chian CF, Su WL, Soh LH, Yan HC, Perng WC, Wu CP. Echogenic swirling pattern as a predictor of malignant pleural effusions in patients with malignancies. *Chest*. 2004;126(1):129-134.

21. Leung AN, Müller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. *AJR Am J Roentgenol*. 1990;154(3):487-492.

22. Yilmaz U, Polat G, Sahin N, Soy O, Gulay U. CT in differential diagnosis of benign and malignant pleural disease. *Monaldi Arch Chest Dis*. 2005;63(1):17-22.

23. Traill ZC, Davies RJ, Gleeson FV. Thoracic computed tomography in patients with suspected malignant pleural effusions. *Clin Radiol*. 2001;56(3): 193-196.

24. Hwang JH, Song KS, Park SI, Lim TH, Kwon KH, Goo DE. Subtle pleural metastasis without large effusion in lung cancer patients: preoperative detection on CT. *Korean J Radiol*. 2005;6(2):94-101.

25. Lorigan JG, Libshitz HI. MR imaging of malignant pleural mesothelioma. *J Comput Assist Tomogr*. 1989;13(4):617-620.

26. Davis SD, Henschke CL, Yankelevitz DF, Cahill PT, Yi Y. MR imaging of pleural effusions. *J Comput Assist Tomogr*. 1990;14(2):192-198.

27. Falaschi F, Battolla L, Zampa V, et al. Comparison of computerized tomography and magnetic resonance in the assessment of benign and malignant pleural diseases [in Italian]. *Radiol Med (Torino)*. 1996;92(6):713-718.

28. Hierholzer J, Luo L, Bittner RC, et al. MRI and CT in the differential diagnosis of pleural disease. *Chest*. 2000;118(3):604-609.

29. Luo L, Hierholzer J, Bittner RC, Chen J, Huang L. Magnetic resonance imaging in distinguishing malignant from benign pleural disease. *Chin Med J (Engl)*. 2001;114(6):645-649.

30. McLoud TC. CT and MR in pleural disease. *Clin Chest Med*. 1998; 19(2):261-276.

31. Duysinx B, Nguyen D, Louis R, et al. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. *Chest*. 2004; 125(2):489-493.

32. Erasmus JJ, McAdams HP, Rossi SE, Goodman PC, Coleman RE, Patz EF. FDG PET of pleural effusions in patients with non-small cell lung cancer. *AJR Am J Roentgenol*. 2000;175(1):245-249.

33. Schaffler GJ, Wolf G, Schoellnast H, et al. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET. *Radiology*. 2004 Jun;231(3):858-865. Epub 2004 Apr 22.

34. Kwek BH, Aquino SL, Fischman AJ. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. *Chest*. 2004;125(6):2356-2360.

35. Munden RF. A new era in thoracic oncologic imaging: CT-PET [editorial]. *J Thorac Imaging*. 2006;21(2):97-98.

36. Toaff JS, Metser U, Gottfried M, et al. Differentiation between malignant and benign pleural effusion in patients with extra-pleural primary malignancies: assessment with positron emission tomography-computed tomography. *Invest Radiol*. 2005;40(4):204-209.

37. Weiss N, Solomon SB. Talc pleurodesis mimics pleural metastases: differentiation with positron emission tomography/computed tomography. *Clin Nucl Med*. 2003;28(10):811-814.

38. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s—meta-analytic comparison of PET and CT. *Radiology*. 1999;213(2):530-536.

39. Feinsilver SH, Barrows AA, Braman SS. Fiberoptic bronchoscopy and pleural effusion of unknown origin. *Chest*. 1986;90(4):516-519.

40. Chakrabarti B, Ryland I, Sheard J, Warburton CJ, Earis JE. The role of Abrams percutaneous pleural biopsy in the investigation of exudative pleural effusions. *Chest*. 2006;129(6):1549-1555.

41. Thomsen TW, DeLaPena J, Setnik GS. Videos in clinical medicine: thoracentesis. *N Engl J Med*. 2006;355(15):e16.

42. Diacon AH, Schuurmans MM, Theron J, Schubert PT, Wright CA, Bolliger CT. Safety and yield of ultrasound-assisted transthoracic biopsy performed by pulmonologists. *Respiration*. 2004;71(5):519-522.

43. Feller-Kopman D. Therapeutic thoracentesis: the role of ultrasound and pleural manometry. *Curr Opin Pulm Med*. 2007;13(4):312-318.

44. Feller-Kopman D. Ultrasound-guided thoracentesis. *Chest*. 2006; 129(6):1709-1714.

45. Barnes TW, Morgenthaler TI, Olson EJ, Hesley GK, Decker PA, Ryu JH. Sonographically guided thoracentesis and rate of pneumothorax. *J Clin Ultrasound*. 2005;33(9):442-446.

46. Ryu JS, Ryu ST, Kim YS, Cho JH, Lee HL. What is the clinical significance of transudative malignant pleural effusion? *Korean J Intern Med*. 2003;18(4):230-233.

47. Porcel JM, Alvarez M, Salud A, Vives M. Should a cytologic study be ordered in transudative pleural effusions [letter]? *Chest*. 1999;116(6):1836-1837.

48. Heffner JE, Highland K, Brown LK. A meta-analysis derivation of continuous likelihood ratios for diagnosing pleural fluid exudates. *Am J Respir Crit Care Med*. 2003;167(12):1591-1599.

49. Heffner JE, Brown LK, Barbieri CA, Primary Study Investigators. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. *Chest*. 1997;111(4):970-980.

50. Matthai SM, Kini U. Diagnostic value of eosinophils in pleural effusion: a prospective study of 26 cases. *Diagn Cytopathol*. 2003;28(2):96-99.

51. Martinez-Garcia MA, Cases-Viedma E, Cordero-Rodriguez PJ, et al. Diagnostic utility of eosinophils in the pleural fluid. *Eur Respir J*. 2000;15(1): 166-169.

52. Rubins JB, Rubins HB. Etiology and prognostic significance of eosinophilic pleural effusions: a prospective study. *Chest*. 1996;110(5):1271-1274.

53. Branca P, Rodriguez RM, Rogers JT, Ayo DS, Moyers JP, Light RW. Routine measurement of pleural fluid amylase is not indicated. *Arch Intern Med*. 2001;161(2):228-232.

54. Villena V, Perez V, Pozo F, et al. Amylase levels in pleural effusions: a consecutive unselected series of 841 patients. *Chest*. 2002;121(2):470-474.

55. Sahn SA, Good JT Jr. Pleural fluid pH in malignant effusions: diagnostic, prognostic, and therapeutic implications. *Ann Intern Med*. 1988;108(3):345-349.

56. Gottehrer A, Taryle DA, Reed CE, Sahn SA. Pleural fluid analysis in malignant mesothelioma: prognostic implications. *Chest*. 1991;100(4):1003-1006.

57. Good JT Jr, Taryle DA, Maulitz RM, Kaplan RL, Sahn SA. The diagnostic value of pleural fluid pH. *Chest*. 1980;78(1):55-59.

58. Sanchez-Armengol A, Rodriguez-Panadero F. Survival and talc pleurodesis in metastatic pleural carcinoma, revisited: report of 125 cases. *Chest*. 1993;104(5):1482-1485.

59. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data. *Chest*. 2000;117(1):87-95.

60. Heffner JE, Heffner JN, Brown LK. Multilevel and continuous pleural fluid pH likelihood ratios for evaluating malignant pleural effusions. *Chest*. 2003;123(6):1887-1894.

61. Nance KV, Shermer RW, Askin FB. Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination. *Mod Pathol*. 1991; 4(3):320-324.

62. Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. *Mayo Clin Proc*. 1985;60(3):158-164.

63. Woenckhaus M, Grepmeier U, Werner B, et al. Microsatellite analysis of pleural supernatants could increase sensitivity of pleural fluid cytology. *J Mol Diagn*. 2005;7(4):517-524.

64. Benlloch S, Galbis-Caravajal JM, Martin C, et al. Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion. *Cancer*. 2006;107(8):1859-1865.

65. Sallach SM, Sallach JA, Vasquez E, Schultz L, Kvale P. Volume of pleural fluid required for diagnosis of pleural malignancy. *Chest*. 2002;122(6): 1913-1917.

66. Ong KC, Indumathi V, Poh WT, Ong YY. The diagnostic yield of pleural fluid cytology in malignant pleural effusions. *Singapore Med J*. 2000; 41(1):19-23.

67. Garcia LW, Ducatman BS, Wang HH. The value of multiple fluid specimens in the cytological diagnosis of malignancy. *Mod Pathol*. 1994;7(6):665-668.

68. Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. *Chest*. 2004;126(6):1757-1763.

69. Lee JH, Chang JH. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. *Chest*. 2005;128(4):2298-2303.

70. Shitrit D, Zingerman B, Shitrit AB, Shlomi D, Kramer MR. Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. *Oncologist*. 2005; 10(7):501-507.

71. Whitaker D. The cytology of malignant mesothelioma. *Cytopathology*. 2000;11(3):139-151.

72. Robinson BW, Lake RA. Advances in malignant mesothelioma. *N Engl J Med*. 2005;353(15):1591-1603.

73. Lee JH, Hong YS, Ryu JS, Chang JH. p53 and FHIT mutations and microsatellite alterations in malignancy-associated pleural effusion. *Lung Cancer*. 2004;44(1):33-42.

74. Brock MV, Hooker CM, Yung R, et al. Can we improve the cytologic examination of malignant pleural effusions using molecular analysis? *Ann Thorac Surg*. 2005;80(4):1241-1247.

75. Holloway AJ, Diyagama DS, Opeskin K, et al. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. *Clin Cancer Res.* 2006;12(17):5129-5135.

76. Hung MS, Lin CK, Leu SW, Wu MY, Tsai YH, Yang CT. Epidermal growth factor receptor mutations in cells from non-small cell lung cancer malignant pleural effusions. *Chang Gung Med J.* 2006;29(4):373-379.

77. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. *PLoS Med.* 2005 Jan;2(1):e17. Epub 2005 Jan 25.

78. Nakamoto M, Teramoto H, Matsumoto S, Igishi T, Shimizu E. K-ras and rho A mutations in malignant pleural effusion. *Int J Oncol.* 2001;19(5):971-976.

79. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. *Lancet.* 2003;362(9396):1612-1616.

80. Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. *Clin Cancer Res.* 2007;13(17):5076-5081.

81. Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. *Chest.* 2007 Oct;132(4):1239-1246. Epub 2007 Jul 23.

82. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. *N Engl J Med.* 2005;353(15):1564-1573.

83. Posadas EM, Simpkins F, Liotta LA, MacDonald C, Kohn EC. Proteomic analysis for the early detection and rational treatment of cancer—realistic hope? *Ann Oncol.* 2005;16(1):16-22.

84. Fiegl M. The utility of fluorescence in-situ hybridization in the diagnosis of malignant pleural effusion. *Curr Opin Pulm Med.* 2005;11(4):313-318.

85. Osterheld MC, Liette C, Anca M. Image cytometry: an aid for cytological diagnosis of pleural effusions. *Diagn Cytopathol.* 2005;32(3):173-176.

86. Northup JK, Gadre SA, Ge Y, Lockhart LH, Velagaleti GV. Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition? *Eur J Haematol.* 2007;78(2):152-156.

87. Boutin C, Schlesser M, Frenay C, Astoul P. Malignant pleural mesothelioma. *Eur Respir J.* 1998;12(4):972-981.

88. Edmondstone WM. Investigation of pleural effusion: comparison between fibreoptic thoracoscopy, needle biopsy and cytology. *Respir Med.* 1990; 84(1):23-26.

89. McLean AN, Bicknell SR, McAlpine LG, Peacock AJ. Investigation of pleural effusion: an evaluation of the new Olympus LTF semiflexible thoracofiberscope and comparison with Abram's needle biopsy. *Chest.* 1998;114(1): 150-153.

90. Maskell NA, Gleeson FV, Davies RJ. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. *Lancet.* 2003;361(9366):1326-1330.

91. Walshe ADP, Douglas JG, Kerr KM, McKean ME, Godden DJ. An audit of the clinical investigation of pleural effusion. Thorax. 1992;47(9):734-737.

92. Cowie RL, Escreet BC, Goldstein B, Langton ME, Leigh RA. Pleural biopsy: a report of 750 biopsies performed using Abrams's pleural biopsy punch. *S Afr Med J.* 1983;64(3):92-95.

93. Jimenez D, Perez-Rodriguez E, Diaz G, Fogue L, Light RW. Determining the optimal number of specimens to obtain with needle biopsy of the pleura. *Respir Med.* 2002;96(1):14-17.

94. Scott EM, Marshall TJ, Flower CD, Stewart S. Diffuse pleural thickening: percutaneous CT-guided cutting needle biopsy. *Radiology.* 1995;194(3):867-870.

95. Benamore RE, Scott K, Richards CJ, Entwisle JJ. Image-guided pleural biopsy: diagnostic yield and complications. *Clin Radiol.* 2006;61(8):700-705.

96. Tassi GF, Davies RJ, Noppen M. Advanced techniques in medical thoracoscopy. *Eur Respir J.* 2006;28(5):1051-1059.

97. Mathur PN, Astoul P, Boutin C. Medical thoracoscopy: technical details. *Clin Chest Med.* 1995;16(3):479-486.

98. Ernst A, Hersh CP, Herth F, et al. A novel instrument for the evaluation of the pleural space: an experience in 34 patients. *Chest.* 2002;122(5):1530-1534.

99. Munavvar M, Khan MA, Edwards J, Waqaruddin Z, Mills J. The autoclavable semirigid thoracoscope: the way forward in pleural disease? *Eur Respir J.* 2007;29(3):571-574. Epub 2007 Jan 10.

100. Lee YC, Light RW. Management of malignant pleural effusions. *Respirology.* 2004;9(2):148-156.

101. Maskell NA, Butland RJ. BTS guidelines for the investigation of a unilateral pleural effusion in adults. *Thorax.* 2003;58(suppl 2):ii8-ii17.

102. Baas P, Triesscheijn M, Burgers S, van Pel R, Stewart F, Aalders M. Fluorescence detection of pleural malignancies using 5-aminolaevulinic acid. *Chest.* 2006;129(3):718-724.

103. Chrysanthidis MG, Janssen JP. Autofluorescence videothoracoscopy in exudative pleural effusions: preliminary results. *Eur Respir J.* 2005;26(6):989-992.

104. Bueno R, Reblando J, Glickman J, Jaklitsch MT, Lukanich JM, Sugarbaker DJ. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. *Ann Thorac Surg.* 2004;78(5):1774-1776.

105. Ferrer J, Roldan J, Teixidor J, Pallisa E, Gich I, Morell F. Predictors of pleural malignancy in patients with pleural effusion undergoing thoracoscopy. *Chest.* 2005;127(3):1017-1022.

106. Sahn SA. Management of malignant pleural effusions. *Monaldi Arch Chest Dis.* 2001;56(5):394-399.

107. Huggins JT, Doelken P. Pleural manometry. *Clin Chest Med.* 2006; 27(2):229-240.

108. Feller-Kopman D, Walkey A, Berkowitz D, Ernst A. The relationship of pleural pressure to symptom development during therapeutic thoracentesis. *Chest.* 2006;129(6):1556-1560.

109. Groth G, Gatzemeier U, Haussingen K, et al. Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). *Ann Oncol.* 1991;2(3):213-215.

110. Antunes G, Neville E, Duffy J, Ali N, BTS Pleural Disease Group, a subcommittee of the BTS Standards of Care Committee. BTS guidelines for the management of malignant pleural effusions. *Thorax.* 2003;58(suppl 2):ii29-ii38.

111. Antony VB, Loddenkemper R, Astoul P, et al. Management of malignant pleural effusions. *Eur Respir J.* 2001;18(2):402-419.

112. Marom EM, Patz EF Jr, Erasmus JJ, McAdams HP, Goodman PC, Herndon JE. Malignant pleural effusions: treatment with small-bore-catheter thoracostomy and talc pleurodesis. *Radiology.* 1999;210(1):277-281.

113. Schulze M, Boehle AS, Kurdow R, Dohrmann P, Henne-Bruns D. Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients. *Ann Thorac Surg.* 2001;71(6):1809-1812.

114. Jones GR. Treatment of recurrent malignant pleural effusion by iodized talc pleurodesis. *Thorax.* 1969;24(1):69-73.

115. Dresler CM, Olak J, Herndon JE II, et al, Cooperative Groups Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, North Central Cooperative Oncology Group, Radiation Oncology Therapy Group. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. *Chest.* 2005;127(3):909-915.

116. Bernard A, de Dompsure RB, Hagry O, Favre JP. Early and late mortality after pleurodesis for malignant pleural effusion. *Ann Thorac Surg.* 2002; 74(1):213-217.

117. Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. *Chest.* 2000;117(1):73-78.

118. Steger V, Mika U, Toomes H, et al. Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses. *Ann Thorac Surg.* 2007;83(6):1940-1945.

119. Boland GW, Gazelle GS, Girard MJ, Mueller PR. Asymptomatic hydropneumothorax after therapeutic thoracentesis for malignant pleural effusions. *AJR Am J Roentgenol.* 1998;170(4):943-946.

120. Chang YC, Patz EF Jr, Goodman PC. Pneumothorax after small-bore catheter placement for malignant pleural effusions. *AJR Am J Roentgenol.* 1996;166(5):1049-1051.

121. Heidecker J, Huggins JT, Sahn SA, Doelken P. Pathophysiology of pneumothorax following ultrasound-guided thoracentesis. *Chest.* 2006;130(4): 1173-1184.

122. Huggins JT, Sahn SA, Heidecker J, Ravenel JG, Doelken P. Characteristics of trapped lung: pleural fluid analysis, manometry, and air-contrast chest CT. *Chest.* 2007;131(1):206-213.

123. Crnjac A, Sok M, Kamenik M. Impact of pleural effusion pH on the efficacy of thoracoscopic mechanical pleurodesis in patients with breast carcinoma. *Eur J Cardiothorac Surg.* 2004;26(2):432-436.

124. Lee YC, Baumann MH, Maskell NA, et al. Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists. *Chest.* 2003;124(6):2229-2238.

125. Clementsen P, Evald T, Grode G, Hansen M, Krag Jacobsen G, Faurschou P. Treatment of malignant pleural effusion: pleurodesis using a small percutaneous catheter: a prospective randomized study. *Respir Med.* 1998;92(3):593-596.

126. Patz EF Jr. Malignant pleural effusions: recent advances and ambulatory sclerotherapy. *Chest.* 1998;113(1)(suppl):74S-77S.

127. Patz EF Jr, McAdams HP, Erasmus JJ, et al. Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. *Chest.* 1998;113(5):1305-1311.

128. Parulekar W, Di Primio G, Matzinger F, Dennie C, Bociek G. Use of small-bore vs large-bore chest tubes for treatment of malignant pleural effusions. *Chest.* 2001;120(1):19-25.

129. Hsu WH, Chiang CD, Chen CY, Kwan PC, Hsu JY. Ultrasound-guided small-bore Elecath tube insertion for the rapid sclerotherapy of malignant pleural effusion. *Jpn J Clin Oncol.* 1998;28(3):187-191.
130. Sahin U, Unlu M, Akkaya A, Ornek Z. The value of small-bore catheter thoracostomy in the treatment of malignant pleural effusions. *Respiration.* 2001;68(5):501-505.
131. Sartori S, Tombesi P, Tassinari D, et al. Sonographically guided small-bore chest tubes and sonographic monitoring for rapid sclerotherapy of recurrent malignant pleural effusions. *J Ultrasound Med.* 2004;23(9):1171-1176.
132. Saffran L, Ost DE, Fein AM, Schiff MJ. Outpatient pleurodesis of malignant pleural effusions using a small-bore pigtail catheter. *Chest.* 2000; 118(2):417-421.
133. Goodman A, Davies CW. Efficacy of short-term versus long-term chest tube drainage following talc slurry pleurodesis in patients with malignant pleural effusions: a randomised trial. *Lung Cancer.* 2006 Oct;54(1):51-55. Epub 2006 Aug 21.
134. Yildirim E, Dural K, Yazkan R, et al. Rapid pleurodesis in symptomatic malignant pleural effusion. *Eur J Cardiothorac Surg.* 2005;27(1):19-22.
135. Spiegler PA, Hurewitz AN, Groth ML. Rapid pleurodesis for malignant pleural effusions. *Chest.* 2003;123(6):1895-1898.
136. Marom EM, Erasmus JJ, Herndon JE II, Zhang C, McAdams HP. Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions. *AJR Am J Roentgenol.* 2002;179(1):105-108.
137. Pollak JS. Malignant pleural effusions: treatment with tunneled long-term drainage catheters. *Curr Opin Pulm Med.* 2002;8(4):302-307.
138. Verfaillie G, Herreweghe RV, Lamote J, Noppen M, Sacre R. Use of a Port-a-Cath system in the home setting for the treatment of symptomatic recurrent malignant pleural effusion. *Eur J Cancer Care (Engl).* 2005;14(2): 182-184.
139. Alisky JM. Implantable central venous access ports for minimally invasive repetitive drainage of pleural effusions. *Med Hypotheses.* 2007;68(4):910-911. Epub 2007 Jan 17.
140. Jacobi CA, Wenger FA, Schmitz-Rixen T, Muller JM. Talc pleurodesis in recurrent pleural effusions. *Langenbecks Arch Surg.* 1998;383(2):156-159.
141. Lee P, Colt HG. A spray catheter technique for pleural anesthesia: a novel method for pain control before talc poudrage. *Anesth Analg.* 2007; 104(1):198-200.
142. Mager HJ, Maesen B, Verzijlbergen F, Schramel F. Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis. *Lung Cancer.* 2002;36(1):77-81.
143. Dryzer SR, Allen ML, Strange C, Sahn SA. A comparison of rotation and nonrotation in tetracycline pleurodesis. *Chest.* 1993;104(6):1763-1766.
144. Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. *Eur J Cardiothorac Surg.* 2006 May;29(5):829-838. Epub 2006 Apr 12.
145. Teixeira LR, Vargas FS, Acencio MM, et al. Influence of antiinflammatory drugs (methylprednisolone and diclofenac sodium) on experimental pleurodesis induced by silver nitrate or talc. *Chest.* 2005;128(6):4041-4045.
146. Teixeira LR, Wu W, Chang DS, Light RW. The effect of corticosteroids on pleurodesis induced by doxycycline in rabbits. *Chest.* 2002;121(1):216-219.
147. Xie C, Teixeira LR, McGovern JP, Light RW. Systemic corticosteroids decrease the effectiveness of talc pleurodesis. *Am J Respir Crit Care Med.* 1998;157(5, pt 1):1441-1444.
148. Haddad FJ, Younes RN, Gross JL, Deheinzelin D. Pleurodesis in patients with malignant pleural effusions: talc slurry or bleomycin? Results of a prospective randomized trial. *World J Surg.* 2004 Aug;28(8):749-753. Epub 2004 Aug 3.
149. Liao H, Guo Y, Jun Na M, Lane KB, Light RW. The short-term administration of Ketoprofen does not decrease the effect of pleurodesis induced by talc or doxycycline in rabbits. *Respir Med.* 2007;101(5):963-968. Epub 2006 Oct 23.
150. Hsu LH, Soong TC, Feng AC, Liu MC. Intrapleural urokinase for the treatment of loculated malignant pleural effusions and trapped lungs in medically inoperable cancer patients. *J Thorac Oncol.* 2006;1(5):460-467.
151. Gasparri R, Leo F, Veronesi G, et al. Video-assisted management of malignant pleural effusion in breast carcinoma. *Cancer.* 2006;106(2):271-276.
152. Arapis K, Caliandro R, Stern JB, Girard P, Debrosse D, Gossot D. Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients. *Surg Endosc.* 2006 Jun;20:919-923. Epub 2006 May 2.
153. Paschoalini Mda S, Vargas FS, Marchi E, et al. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions. *Chest.* 2005;128(2):684-689.
154. Marrazzo A, Noto A, Casa L, et al. Video-thoracoscopic surgical pleurodesis in the management of malignant pleural effusion: the importance of an early intervention. *J Pain Symptom Manage.* 2005;30(1):75-79.
155. Kolschmann S, Ballin A, Gillissen A. Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. *Chest.* 2005;128(3):1431-1435.
156. Kilic D, Akay H, Kavukcu S, et al. Management of recurrent malignant pleural effusion with chemical pleurodesis. *Surg Today.* 2005;35(8):634-638.
157. Stefani A, Natali P, Casali C, Morandi U. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion: a prospective comparative study. *Eur J Cardiothorac Surg.* 2006;30(6):827-832.
158. Porcel JM, Salud A, Nabal M, Vives M, Esquerda A, Rodriguez-Panadero F. Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions. *Support Care Cancer.* 2006 May;14(5):475-478. Epub 2006 Jan 10.
159. Heffner JE, Standerfer RJ, Torstveit J, Unruh L. Clinical efficacy of doxycycline for pleurodesis. *Chest.* 1994;105(6):1743-1747.
160. Kuzdzal J, Sladek K, Wasowski D, et al. Talc powder vs doxycycline in the control of malignant pleural effusion: a prospective, randomized trial. *Med Sci Monit.* 2003;9(6):PI54-P159.
161. Sartori S, Tassinari D, Ceccotti P, et al. Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions. *J Clin Oncol.* 2004;22(7):1228-1233.
162. Moffett MJ, Ruckdeschel JC. Bleomycin and tetracycline in malignant pleural effusions: a review. *Semin Oncol.* 1992;19(2)(suppl 5):59-62.
163. Ukale V, Agrenius V, Hillerdal G, Mohlkert D, Widstrom O. Pleurodesis in recurrent pleural effusions: a randomized comparison of a classical and a currently popular drug. *Lung Cancer.* 2004;43(3):323-328.
164. Stiksa G, Korsgaard R, Simonsson BG. Treatment of recurrent pleural effusion by pleurodesis with quinacrine: comparison between instillation by repeated thoracenteses and by tube drainage. *Scand J Respir Dis.* 1979;60(4): 197-205.
165. Bayly TC, Kisner DL, Sybert A, Macdonald JS, Tsou E, Schein PS. Tetracycline and quinacrine in the control of malignant pleural effusions: a randomized trial. *Cancer.* 1978;41(3):1188-1192.
166. Koldsland S, Svennevig JL, Lehne G, Johnson E. Chemical pleurodesis in malignant pleural effusions: a randomised prospective study of mepacrine versus bleomycin. *Thorax.* 1993;48(8):790-793.
167. Banerjee AK, Willetts I, Robertson JF, Blamey RW. Pleural effusion in breast cancer: a review of the Nottingham experience. *Eur J Surg Oncol.* 1994; 20(1):33-36.
168. Olivares-Torres CA, Laniado-Laborin R, Chavez-Garcia C, Leon-Gastelum C, Reyes-Escamilla A, Light RW. Iodopovidone pleurodesis for recurrent pleural effusions. *Chest.* 2002;122(2):581-583.
169. Agarwal R, Aggarwal AN, Gupta D. Efficacy and safety of iodopovidone pleurodesis through tube thoracostomy. *Respirology.* 2006;11(1):105-108.
170. Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Efficacy and safety of iodopovidone in chemical pleurodesis: a meta-analysis of observational studies. *Respir Med.* 2006 Nov;100(11):2043-2047. Epub 2006 Mar 30.
171. Kelly-Garcia J, Roman-Berumen JF, Ibarra-Perez C. Iodopovidone and bleomycin pleurodesis for effusions due to malignant epithelial neoplasms. *Arch Med Res.* 1997 Winter;28(4):583-585.
172. Agarwal R. Iodopovidone: an inexpensive and effective agent for chemical pleurodesis [letter]. *Lung Cancer.* 2007 Feb;55(2):253-254. Epub 2006 Nov 21.
173. Foresti V. Intrapleural *Corynebacterium parvum* for recurrent malignant pleural effusions. *Respiration.* 1995;62(1):21-26.
174. Hillerdal G, Kiviloog J, Nou E, Steinholtz L. *Corynebacterium parvum* in malignant pleural effusion: a randomized prospective study. *Eur J Respir Dis.* 1986;69(3):204-206.
175. McLeod DT, Calverley PM, Millar JW, Horne NW. Further experience of *Corynebacterium parvum* in malignant pleural effusion. *Thorax.* 1985;40(7): 515-518.
176. Senyigit A, Bayram H, Babayigit C, Topcu F, Balci AE, Satici O. Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases. *Respiration.* 2000;67(6):623-629.
177. Chella A, Ribechini A, Dini P, Adamo C, Mussi A, Angeletti CA. Treatment of malignant pleural effusion by percutaneous catheter drainage and chemical pleurodesis [in Italian]. *Minerva Chir.* 1994;49(11):1077-1082.
178. Barbetakis N, Antoniadis T, Tsilikas C. Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer. *World J Surg Oncol.* 2004;2(1):16. doi:10.1186/1477-7819-2-16.
179. Barbetakis N, Vassiliadis M, Kaplanis K, Valeri R, Tsilikas C. Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer. *BMC Palliat Care.* 2004;3(1):4. doi:10.1186/1472-684X-3-4.
180. Kelly J, Holmes EC, Rosen G. Mitoxantrone for malignant pleural effusion due to metastatic sarcoma. *Surg Oncol.* 1993;2(5):299-301.

181. Wilkins HE III, Connolly MM, Grays P, Marquez G, Nelson D. Recombinant interferon alpha-2b in the management of malignant pleural effusions. *Chest*. 1997;111(6):1597-1599.
182. Sartori S, Trevisani L, Nielsen I, Tassinari D, Abbasciano V. Intracavitary bleomycin vs interferon in the management of malignant pleural effusions [letter]. *Chest*. 1998;113(4):1145-1146.
183. Ren S, Terman DS, Bohach G, et al. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. *Chest*. 2004;126(5):1529-1539.
184. Ishida A, Miyazawa T, Miyazu Y, et al. Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non-small cell lung cancer. *Respirology*. 2006;11(1):90-97.
185. Seto T, Ushijima S, Yamamoto H, et al, Kyushu Yamaguchi Thoracic Oncology Group. Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial. *Br J Cancer*. 2006 Sep 18;95(6):717-721. Epub 2006 Aug 29.
186. Kasahara K, Shibata K, Shintani H, et al. Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer. *Anticancer Res*. 2006;26(2B):1495-1499.
187. Luh KT, Yang PC, Kuo SH, Chang DB, Yu CJ, Lee LN. Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer: a randomized trial. *Cancer*. 1992;69(3):674-679.
188. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. *Cochrane Database Syst Rev*. 2004;1:CD002916.
189. Debeljak A, Kecelj P, Triller N, et al. Talc pleurodesis: comparison of talc slurry instillation with thoracoscopic talc insufflation for malignant pleural effusions. *J BUON*. 2006;11(4):463-467.
190. Ong KC, Indumathi V, Raghuram J, Ong YY. A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions. *Respirology*. 2000;5(2):99-103.
191. Nasreen N, Mohammed KA, Brown S, et al. Talc mediates angiostasis in malignant pleural effusions via endostatin induction. *Eur Respir J*. 2007 Apr;29(4):761-769. Epub 2007 Jan 24.
192. Marchi E, Vargas FS, Acencio MM, Antonangelo L, Genofre EH, Teixeira LR. Evidence that mesothelial cells regulate the acute inflammatory response in talc pleurodesis. *Eur Respir J*. 2006 Nov;28(5):929-932. Epub 2006 Jul 26.
193. Antony VB, Nasreen N, Mohammed KA, et al. Talc pleurodesis: basic fibroblast growth factor mediates pleural fibrosis [letter]. *Chest*. 2004;126(5):1522-1528.
194. Brant A, Eaton T. Serious complications with talc slurry pleurodesis. *Respirology*. 2001;6(3):181-185.
195. Medford AR, Maskell NA. A national survey of oncologist and chest physicians' attitudes towards empirical anti-oestrogen therapy, early pleurodesis and preference of sclerosing agent in malignant breast and ovarian pleural disease. *Palliat Med*. 2005;19(5):430-431.
196. de Campos JR, Vargas FS, de Campos Werebe E, et al. Thoracoscopy talc poudrage : a 15-year experience. *Chest*. 2001;119(3):801-806.
197. Scalzetti EM. Unilateral pulmonary edema after talc pleurodesis. *J Thorac Imaging*. 2001;16(2):99-102.
198. Ferrer J, Montes JF, Villarino MA, Light RW, Garcia-Valero J. Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis. *Chest*. 2002;122(3):1018-1027.
199. Froudarakis ME, Klimathianaki M, Pougounias M. Systemic inflammatory reaction after thoracoscopic talc poudrage. *Chest*. 2006;129(2):356-361.
200. Viallat JR, Rey F, Astoul P, Boutin C. Thoracoscopic talc poudrage pleurodesis for malignant effusions: a review of 360 cases. *Chest*. 1996;110(6):1387-1393.
201. Weissberg D, Ben-Zeev I. Talc pleurodesis. Experience with 360 patients. *J Thorac Cardiovasc Surg*. 1993;106(4):689-695.
202. Noppen M. Who's (still) afraid of talc [editorial]? *Eur Respir J*. 2007;29(4):619-621.
203. Janssen JP, Collier G, Astoul P, et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. *Lancet*. 2007;369(9572):1535-1539.
204. Kuzniar TJ, Blum MG, Kasibowska-Kuzniar K, Mutlu GM. Predictors of acute lung injury and severe hypoxemia in patients undergoing operative talc pleurodesis. *Ann Thorac Surg*. 2006;82(6):1976-1981.
205. Lee P, Colt HG. Rigid and semirigid pleuroscopy: the future is bright. *Respirology*. 2005;10(4):418-425.
206. Katlic MR. Video-assisted thoracic surgery utilizing local anesthesia and sedation. *Eur J Cardiothorac Surg*. 2006 Sep;30(3):529-532. Epub 2006 Aug 2.
207. Brega-Massone PP, Lequaglie C, Magnani B, Ferro F, Cataldo I. Chemical pleurodesis to improve patients' quality of life in the management of malignant pleural effusions: the 15 year experience of the National Cancer Institute of Milan. *Surg Laparosc Endosc Percutan Tech*. 2004;14(2):73-79.
208. Cardillo G, Facciolo F, Carbone L, et al. Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions. *Eur J Cardiothorac Surg*. 2002;21(2):302-305.
209. Crnjac A. The significance of thoracoscopic mechanical pleurodesis for the treatment of malignant pleural effusions. *Wien Klin Wochenschr*. 2004;116 (suppl 2):28-32.
210. Trotter D, Aly A, Siu L, Knight S. Video-assisted thoracoscopic (VATS) pleurodesis for malignant effusion: an Australian teaching hospital's experience. *Heart Lung Circ*. 2005;14(2):93-97.
211. van den Toorn LM, Schaap E, Surmont VF, Pouw EM, van der Rijt KC, van Klaveren RJ. Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter. *Lung Cancer*. 2005;50(1):123-127.
212. Putnam JB Jr, Walsh GL, Swisher SG, et al. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. *Ann Thorac Surg*. 2000;69(2):369-375.
213. Pollak JS, Burdge CM, Rosenblatt M, Houston JP, Hwu WJ, Murren J. Treatment of malignant pleural effusions with tunneled long-term drainage catheters. *J Vasc Interv Radiol*. 2001;12(2):201-208.
214. Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. *Chest*. 2006;129(2):362-368.
215. Pien GW, Gant MJ, Washam CL, Sterman DH. Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion. *Chest*. 2001;119(6):1641-1646.
216. Musani AI, Haas AR, Seijo L, Wilby M, Sterman DH. Outpatient management of malignant pleural effusions with small-bore, tunneled pleural catheters. *Respiration*. 2004;71(6):559-566.
217. Ohm C, Park D, Vogen M, et al. Use of an indwelling pleural catheter compared with thorascopic talc pleurodesis in the management of malignant pleural effusions. *Am Surg*. 2003;69(3):198-202.
218. Wachsman AM, Hoffer EK, Forauer AR, Silas AM, Gemery JM. Tension pneumothorax after placement of a tunneled pleural drainage catheter in a patient with recurrent malignant pleural effusions. *Cardiovasc Intervent Radiol*. 2007;30(3):531-533.
219. Janes SM, Rahman NM, Davies RJ, Lee YC. Catheter-tract metastases associated with chronic indwelling pleural catheters. *Chest*. 2007;131(4):1232-1234.
220. Putnam JB Jr, Light RW, Rodriguez RM, et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. *Cancer*. 1999;86(10):1992-1999.
221. Petrou M, Kaplan D, Goldstraw P. Management of recurrent malignant pleural effusions: the complementary role talc pleurodesis and pleuroperitoneal shunting. *Cancer*. 1995;75(3):801-805.
222. Genc O, Petrou M, Ladas G, Goldstraw P. The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions. *Eur J Cardiothorac Surg*. 2000;18(2):143-146.
223. Artemiou O, Marta GM, Klepetko W, Wolner E, Muller MR. Pleurovenous shunting in the treatment of nonmalignant pleural effusion. *Ann Thorac Surg*. 2003;76(1):231-233.
224. Gupta D, Ross K, Piacentino V III, et al. Use of LeVeen pleuroperitoneal shunt for refractory high-volume chylothorax. *Ann Thorac Surg*. 2004;78(1):e9-e12.

The Symposium on Solid Tumors will continue in the March issue.